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Purpose: To assess the effectiveness and tolerability of cyclosporine ophthalmic emulsion (CsA) 0.05% in patients 
with moderate to severe dry eye disease in Korea.
Methods: This was a prospective, multicenter, open-label, surveillance study of 392 Korean patients with moderate 
to severe dry eye disease who were treated with CsA 0.05% for three months. An assessment of effectiveness 
was performed at baseline, and after 1, 2, and 3 months. The primary effectiveness outcomes were changes in 
ocular symptoms and Schirmer score. The secondary effectiveness outcomes were a change in conjunctival 
staining, use of artificial tears, global evaluation of treatment, and patient satisfaction. The primary safety out-
come was the incidence and nature of adverse events. 
Results: A total of 362 patients completed the study. After three months, all ocular symptom scores were sig-
nificantly reduced compared to the baseline values, while the Schirmer scores were significantly increased rela-
tive to baseline (p < 0.0001). After three months, there were significant reductions from baseline in conjunctival 
staining (p < 0.01) and use of artificial tears (p < 0.0001). According to clinicians’ global evaluations, most pa-
tients (>50%) experienced at least a 25% to 50% improvement in symptoms from baseline at each follow-up visit. 
The majority of patients (72.0%) were satisfied with the treatment results, and 57.2% reported having no or mild 
symptoms after treatment. The most common adverse events were ocular pain (11.0%). 
Conclusions: Our findings indicate that CsA 0.05% is an effective and tolerable treatment for dry eye disease in 
Korean clinical practice.
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Dry eye disease is a common condition that is particularly 
prevalent in Asia and that has a high burden of disease for 
patients. Indeed, dry eye disease is one of the most common 
conditions encountered by ophthalmologists [1] and ac-
counts for 15% to 40% of cases at eye clinics across Asia 
[2-4]. Asian populations may experience a higher prevalence 
of dry eye disease [5-9] than do Caucasian populations 
[10-12]. Further, there is evidence suggesting that the in-
cidence of dry eye disease in Asia may be increasing [13]. 
This increasing incidence is concerning as dry eye disease 
poses many significant burdens for patients, including direct 
and indirect costs [14,15], reduced quality of life [16], limi-
tations to daily activities, reduced social and physical func-
tioning, and decreased workplace productivity [15]. Given the 
high prevalence of dry eye disease in Asia and the potential 
burden of this disease on patients, it is important to clinicians 
that approved treatments meet expectations in clinical practice.
Dry eye disease is a multifactorial disease for which there 
are several treatments. Ocular inflammation and changes in 
tear osmolarity are the two factors that underlie dry eye dis-
ease and can cause ocular discomfort, visual disturbance, tear 
film instability, and damage to the ocular surface [17]. The 
recommended treatments for mild dry eye disease are life-
style changes and the use of artificial tears [18,19]. However, 
patients with moderate to severe disease may require anti-in-
flammatory medications or surgery [20]. Cyclosporine oph-
thalmic emulsion (CsA) 0.05% is a topical antiinflammatory 
that has been approved by the United States Food and Drug 
Administration for treatment of moderate to severe dry eye Korean J Ophthalmol Vol.25, No.6, 2011
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disease. Several clinical trials have investigated the efficacy 
and tolerability of CsA 0.05% for treatment of dry eye dis-
ease in the United States [21-23] and in Korea [24,25]. While 
these clinical trials have established the efficacy of CsA 
0.05% in select patient populations, only two, small-scale 
(less than 30 patients) Korean studies [26,27] have inves-
tigated the clinical effectiveness of CsA 0.05% for treatment 
of dry eye disease. Additional evidence from a larger pop-
ulation is needed to verify whether CsA 0.05% is effective 
and tolerable in clinical practice. The aim of our study was to 
assess the effectiveness and tolerability of CsA 0.05% in pa-
tients with moderate to severe dry eye disease in a Korean 
clinical practice setting.
Materials and Methods 
Study design and setting
This prospective, multicenter, open-label, surveillance 
study was conducted between August 2006 and March 2009 
at 26 clinical practice sites in Korea. At the time this study 
was conducted, there was no local requirement for ethics 
approval. All patients provided voluntary, signed informed 
consent before the commencement of any study-related 
procedures. 
Study participants
The main inclusion criteria for enrollment were age >18 
years; a diagnosis of moderate to severe dry eye disease 
(based on clinicians’ standard clinical practices); sympto-
matic dry eye disease; and nonresponsiveness to conven-
tional treatment such as artificial tear drops, gels, ointments, 
and punctal plugs. 
The main exclusion criteria were use of systemic or topical 
CsA in the previous 90 days; anticipated use of any temporal 
punctal plugs during the study; women who were pregnant, 
planning a pregnancy, or lactating; end-stage lacrimal dis-
ease or dry eye disease caused by destruction of goblet cells; 
active ocular infections; and suspected hypersensitivity to 
any of the ingredients in the CsA formulation. 
Study protocol
The study comprised a baseline visit and three follow-up 
visits after 1, 2, and 3 months of treatment. One drop of CsA 
0.05% (Restasis
®; Allergan Inc., Irvine, CA, USA) was ap-
plied every 12 hours to each eye as monotherapy or adjunct 
therapy. The use of artificial tear substitutes was continued in 
all applicable patients. New treatments, including any eye-
drops or punctal plug, were not added after enrollment.
At each study visit, patients were examined according to 
the clinicians’ standard clinical practices. In addition, symp-
toms of ocular discomfort (i.e., stinging/burning, itching, 
sandiness/grittiness, blurred vision, light sensitivity, pain, 
and soreness), Schirmer scores, use of artificial tears, global 
evaluation of improvement, and adverse events were re-
corded at each visit. There was an optional measurement of 
conjunctival staining (Oxford score) performed at baseline 
and after three months of treatment. Clinicians’ also assessed 
global evaluation of improvement in symptoms of dry eye 
disease from baseline at each follow-up visit according to the 
following categories; >90% improvement, 75% to 90% im-
provement, 25% to 75% improvement, condition unchanged, 
and condition worsened. Patient satisfaction was assessed 
through the completion of a four-question survey at the final 
study visit. The exit survey comprised the following ques-
tions: How are your chronic dry eye symptoms?; With 
Restasis
®, how does your chronic dry eye condition now af-
fect your normal daily activities?; Overall, how satisfied are 
you with Restasis
®?; How quickly did Restasis
® start work-
ing to relieve your chronic dry eye symptoms? Scoring for 
each question was based on a scale bar from 0 (no symptom) 
to 10 (maximum symptom experienced). 
Outcome measures
The primary effectiveness outcome measures included 
changes in symptom scores (rated on a scale of 0 [no symp-
toms] to 4 [always have symptoms]) and Schirmer scores 
(mm, with or without anesthesia [28]). The secondary effec-
tiveness outcome measures included change in conjunctival 
staining (rated on a scale of 0 to 5), use of artificial tears, 
global evaluation of the treatment, and patient satisfaction 
with the treatment. The primary safety outcome measure was 
the incidence and nature of adverse events. 
Statistical analysis 
All data are summarized using frequency distributions 
and/or descriptive summary statistics (mean and standard de-
viation [SD]). The effectiveness analysis population included 
all patients who completed the study. The tolerability analy-
sis population included all patients who were enrolled in the 
study. All statistical analyses included data for the treated eye 
or the mean data for both eyes (if patients received treatment 
for both eyes). Schirmer scores (with or without anesthesia) 
for all visits were compared using a repeated measures analy-
sis of variance. For all other effectiveness variables, the changes 
from baseline data were compared using a paired sample 
t-test. Patients with missing baseline values were excluded 
from the analyses, and missing post-treatment data were in-
ferred by carrying forward the subsequent observation. For 
all analyses, statistical significance was set at p ≤ 0.05. 
Statistical analyses were performed using SAS ver. 9.1.3 
(SAS Inc., Cary, NC, USA).  
Results
A total of 392 patients were enrolled in the study and in-YS Byun, et al. Cyclosporine 0.05% for Dry Eye Disease in Korea
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Table 1. Baseline demographics and disease character-
istics of patients with dry eye disease
Characteristic, n (%) n = 392
Female
* 279 (73.8)
Age ≥50 yr
†  174 (45.2)
Duration of disease
‡
Newly diagnosed 14 (3.6)
<1 yr  84 (21.9)
1-5 yr 197 (51.3)
6-10 yr  55 (14.3)
>10 yr 34 (8.9)
Previous ocular surgery
§ 97 (26.0)
*Data not available for 14 patients; 
†Data not available for 7 
patients; 
‡Data not available for 8 patients; 
§Data not available for 
19 patients.
Table 2. Symptom scores
* for patients with dry eye disease who were treated with cyclosporine ophthalmic emulsion 
0.05% for three months
Symptom Baseline 1 mon  2 mon 3 mon
Stinging/burning (n = 331) 2.2 ± 1.4  1.6 ± 1.2
† 1.3 ± 1.1
† 1.1 ± 1.1
†
Itching (n = 312) 1.2 ± 1.3  0.8 ± 1.0
† 0.6 ± 0.9
†  0.5 ± 0.8
†
Sandiness/grittiness (n = 338) 2.4 ± 1.2  1.7 ± 1.1
† 1.3 ± 1.0
†  1.0 ± 0.9
†
Blurred vision (n = 325) 2.0 ± 1.4  1.4 ± 1.2
†  1.0 ± 1.1
†  0.8 ± 1.0
†
Light sensitivity (n = 312) 2.0 ± 1.5  1.4 ± 1.4
†  1.1 ± 1.3
†  0.9 ± 1.2
†
Pain or soreness (n = 323) 2.0 ± 1.3  1.5 ± 1.1
†  1.1 ± 1.1
†  0.9 ± 1.0
†
All data are presented as mean ± standard deviation.
*A score of 0 = no symptoms, a score of 4 = always have symptoms; 
†p < 0.0001 for the study visit compared with baseline. 
With anaesthesia (n = 279)
Without anesthesia (n = 299)
  Baseline                   1                        2                          3
Visit
(mon)
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Fig. 1. Schirmer scores for patients with dry eye disease who were 
treated with cyclosporine ophthalmic emulsion 0.05% for three 
months. Schirmer scores (change from baseline, mm) were assessed 
with and without anesthesia. Data are presented as mean ± standard 
deviation. 
*p < 0.0001 compared with baseline (both with and 
without anesthesia).
cluded in the safety and tolerability analysis; 362 (92.3%) pa-
tients completed the study and were included in the effective-
ness analysis. The main reasons for study discontinuation 
were loss to follow-up (n = 21 patients) and adverse events 
(n = 6 patients). Patients were predominantly female, and 
slightly less than half were 50 years of age or older (Table 1). 
Most patients had been diagnosed with moderate to severe 
dry eye disease for one to five years, and approximately 
one-quarter had undergone a previous ocular surgery.    
Treatment with CsA 0.05% significantly improved symp-
tom, Schirmer, and staining scores and reduced the use of ar-
tificial tears. There were significant reductions from baseline 
in all mean ocular symptom scores (stinging/burning, itch-
ing, sandiness/grittiness, blurred vision, light sensitivity, 
pain or soreness) after one month of treatment (p < 0.0001) 
(Table 2) and which persisted for up to three months of treat-
ment (p < 0.0001). There were significant increases from 
baseline in mean Schirmer scores both with and without an-
esthesia at each study visit (p < 0.0001) (Fig. 1). There were 
no significant differences between Schirmer scores with and 
without anesthesia. The baseline conjunctival staining score 
(Oxford score ± SD) was 3.2 ± 2.2, while the corresponding 
score after three months of treatment was 2.8 ± 2.8. After 
three months of treatment, the mean percentage (±SD) reduc-
tion from baseline in conjunctival staining score was -12.8 ± 
64.7% (p < 0.01), and there was a significant reduction from 
baseline in mean (± SD) use of artificial tears (5.6 ± 5.7 and 
4.0 ± 4.5 drops/day for baseline and three months, re-
spectively; p < 0.0001).  
According to clinicians’ global evaluations of treatment 
with CsA 0.05%, the majority of patients experienced an at 
least 25% to 50% improvement at each visit (Fig. 2). A great-
er percentage of patients experienced a 75% to 90% improve-
ment after three months of treatment than after either one or 
two months of treatment. Dry eye disease worsened in three, 
five, and two patients after one, two, and three months of 
treatment, respectively. 
According to the exit survey findings, patients generally 
reported that CsA 0.05% treatment provided relief from dry 
eye symptoms, and that their experience with the treatment 
was positive (Fig. 3). Specifically, most patients (57.2%) re-
ported that they had no or mild symptoms of dry eye disease 
(score of 0 to 4 out of 10, 214 / 374 patients) (Fig. 3A). Most 
patients (55.2%) also reported that their dry eye disease had 
no or little effect on their normal daily living (scores 0 to 4 
out of 10; 206 / 373 patients) (Fig. 3B). The majority of pa-
tients (72.0%) were satisfied or very satisfied with CsA 
0.05% treatment (scores of 5 to 10 out of 10; 270 / 375 pa-
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Fig. 2. Clinicians’ global evaluations of improvement in patients 
with dry eye disease who were treated with cyclosporine ophthalmic 
emulsion 0.05% for three months. Data are presented as the per-
centage of patients with >90% improvement, 75% to 90% im-
provement, 25% to 50% improvement, condition unchanged, or 
condition worsened.
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Fig. 3. Exit survey results 
for patients with dry eye 
disease who were treated 
with cyclosporine ophthalmic 
emulsion 0.05% (Restasis®)
for three months. Data are 
presented as percentage of 
patients responding to the 
following questions: ‘How are 
your chronic dry eye symp-
toms?’ (A); ‘With Restasis®,
how does your chronic dry 
eye now affect your normal 
daily activities? (B); ‘Overall,
how satisfied are you with 
Restasis®?’ (C); and ‘How
quickly did Restasis® start 
working to relieve your chron-
ic dry eye symptoms?’ (D).
tients) (Fig. 3C). For most patients, relief from dry eye symp-
toms began three to five weeks after commencing CsA 
0.05% treatment (209 / 356, 58.7%) (Fig. 3D). 
Treatment with CsA 0.05% was well-tolerated, and very 
few patients discontinued the study because of adverse 
events. There were a total of 97 adverse events during the 
study. The most common adverse events (incidence >5%) 
were ocular pain (43 / 392 patients, 11.0%) and ocular irritation 
(23 / 392 patients, 5.9%). Six patients (1.5%) discontinued 
the study due to adverse events, including three patients 
(0.8%) with ocular irritation, two patients (0.5%) with ocular 
pain, and one patient (0.3%) with ocular hyperemia. There 
were no serious adverse events during the study. 
Discussion
Our study findings suggest that CsA 0.05% is an effective 
and tolerable treatment for moderate to severe dry eye dis-
ease in Korean clinical practice. We found that treatment 
with CsA 0.05% for three months led to improvements in 
both objective (Schirmer and conjunctival staining scores) 
and subjective (symptom scores and artificial tear use) meas-
ures of dry eye disease. Favorable tolerability was indicated 
by the very low percentage of patients who discontinued the 
study, the absence of serious adverse events, and high patient 
satisfaction with treatment. The results of our study extend 
the efficacy findings of earlier clinical trials [24,25] and clin-
ical practice studies [26,27] of CsA 0.05% in Korean patients 
with moderate to severe dry eye disease and support the use 
of CsA 0.05% for treatment of moderate to severe dry eye 
disease in Korean clinical practice. 
Consistent with previous studies, we found that CsA 
0.05% was an effective treatment for dry eye disease as in-
dicated by changes in symptom, Schirmer, and conjunctival 
staining scores, artificial tear use, and clinicians’ global eval-
uations of treatment. The statistically significant reductions 
in symptom scores in our study are similar to those found in 
phase II [22] and phase III [21] clinical trials of CsA 0.05%. 
Likewise, the significant improvements in mean Schirmer 
scores in our study are similar to those found in Korean pa-
tients after short-term (six to eight weeks [25]) and lon-YS Byun, et al. Cyclosporine 0.05% for Dry Eye Disease in Korea
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gerterm (up to three months [24,26,27]) CsA 0.05% treatment. 
Importantly, our study included a much larger number of pa-
tients (n = 362) in the effectiveness analyses compared with 
those in the two previous clinical practice studies performed 
in Korea (n = 23 [27] and n = 26 [26]). The improvements in 
Schirmer scores (with and without anesthesia), conjunctival 
staining score, artificial tear use, and the clinicians’ global 
evaluations of treatment in our study are in agreement with 
those determined in a randomized controlled trial of CsA 
0.05% [21]. The significant reduction in artificial tear use in 
our study is also consistent with findings from a previous 
study, in which the majority (>60%) of patients reported de-
creased artificial tear use after 60 days of CsA 0.05% treat-
ment [29]. Together, these findings confirm that CsA 0.05% 
reduces the symptoms of dry eye disease. Therefore, we 
speculate that CsA 0.05% partially resolves the pathophysio-
logical changes that cause dry eye disease. However, addi-
tional studies are needed to confirm this conclusion.
We found that treatment with CsA 0.05% was generally 
well-tolerated, and that most patient experiences with CsA 
0.05% were positive. The most common adverse events in 
our study (ocular irritation and pain) are known adverse re-
actions to CsA 0.05% [20-22]. The proportion of patients 
who discontinued treatment because of adverse events 
(1.5%) in our study is similar to the proportion (2.2%) in a 
phase II trial of CsA 0.05% [21]. Moreover, the patient-
reported experience with CsA 0.05% in our study is similar 
to that in clinical practice studies performed in the United 
States [29,30]. Our findings regarding patientreported rating 
of symptoms (i.e., no or mild symptoms) and the effect of dry 
eye on daily activities after three months of CsA 0.05% treat-
ment are similar to those of a clinical practice study in which 
patients reported a 30% reduction in symptom severity and 
improvement in their abilities to perform daily activities after 
two months of treatment with CsA 0.05% [29]. Likewise, our 
patientreported satisfaction findings are similar to those of a 
self-reported compliance study in which compliant patients 
had a mean satisfaction score of 7.7 (0 = not at all satisfied, 
10 = very satisfied) after two months of treatment with CsA 
0.05% [30]. 
Our study has a number of limitations that must be 
acknowledged. First, interpretation of our findings is limited 
by the single-arm, open-label study design. However, the 
clinical practice setting enhances the external validity of our 
findings, as does the prospective, multicenter, surveillance 
design. Second, as our patients were not grouped according 
to the cause of dry eye disease, we were unable to determine 
which patients may (or may not) respond to CsA 0.05% 
treatment. Third, we cannot exclude the possibility that im-
provements in dry eye disease were caused by the emulsion 
vehicle or that subjective improvements were a reflection of 
patients’ providing socially desirable answers. However, the 
results of two randomized controlled trials have shown that 
CsA treatment results in significantly greater improvements 
in dry eye disease than does treatment with the emulsion ve-
hicle [21,22]. In addition, the fact that there was agreement 
between clinician and patient evaluations of treatment (i.e., 
treatment resulted in improvement) would argue against the 
possibility that patients provided socially desirable answers. 
Finally, we did not assess patient adherence to study medi-
cation, document the type of artificial tear use, or use a vali-
dated questionnaire for assessing patient satisfaction with 
treatment. Despite these limitations, the use of multiple ob-
jective (i.e., Schirmer and conjunctival staining scores) and 
subjective measures (i.e., symptom scores and artificial tear 
use) has enabled us to provide clinically relevant evidence of 
the effectiveness of CsA 0.05% for treatment of dry eye 
disease.  
In conclusion, the effectiveness and tolerability findings of 
our study support the use of CsA 0.05% for the treatment of 
moderate to severe dry eye disease in the Korean clinical 
practice setting. 
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